Marché de la thérapie génique en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché de la thérapie génique en Amérique du Nord

Le marché nord-américain de la thérapie génique devrait connaître une croissance au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services et de produits avancés. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux produits sur le marché.

La recherche croissante en thérapie génique et ses techniques et développements devraient stimuler davantage la croissance du marché. Cependant, les préoccupations éthiques et de sécurité liées à la mise en œuvre de la méthode devraient entraver la croissance du marché nord-américain de la thérapie génique au cours de la période de prévision. La demande croissante de thérapie génique, un domaine émergent et avancé du génie génétique et des soins de santé, devrait offrir au marché des opportunités d'améliorer les approches thérapeutiques et diagnostiques.

La demande croissante de soins de santé de meilleure qualité pour les cancers et les maladies génétiques devrait stimuler la croissance du marché. Cependant, le coût élevé des diagnostics et le manque de professionnels qualifiés et certifiés devraient constituer un obstacle à la croissance du marché.

Data Bridge Market Research estime que le marché nord-américain de la thérapie génique devrait atteindre 13 418,96 millions USD d'ici 2030, à un TCAC de 18,8 % au cours de la période de prévision. Les produits représentent le segment de type le plus important du marché en raison de l'utilisation croissante des produits de recherche sur les exosomes dans les diagnostics et les thérapies.

Définition du marché de la thérapie génique en Amérique du Nord

Gene therapy is a medical strategy that addresses the underlying genetic issue in order to treat or prevent disease. Instead of utilising drugs or surgery, gene therapy procedures allow doctors to treat a problem by changing a person's genetic composition. A select few disorders, including an eye condition called Leber congenital amaurosis and a muscle condition called spinal muscular atrophy, are being treated with gene therapy. To ensure that they will be secure and efficient, many other gene therapies are undergoing study. Medical professionals aim to soon apply the promising technique of genome editing to cure human illnesses.

The ability to successfully transport a therapeutic gene to a target cell is the most important prerequisite for gene therapy to be successful. Once transported, that gene must go to the cell wall's nucleus, where it will serve as a model for making protein molecules. The principal therapeutic action is then produced by the protein. For instance, cell destruction might be used in the treatment of tumours, whereas cell preservation might be used in the case of neurodegenerative illness. However, strict regulations and standards for the approval and commercialization of products is expected to restrain the market growth.

North America Gene Therapy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Novel approaches of gene therapy

Gene therapy has brought permanent cures for ailments that were previously simply temporary treatments. For a very long period, gene therapy did not work; however, in recent years, effective and long-lasting treated cases have been recorded. For a wide range of hereditary illnesses, including blood abnormalities, immunological deficiencies, vision issues, nerve cell regeneration, metabolic disorders, and different types of cancer, promising outcomes have been attained.

With more specificity and fewer side effects, gene therapy has the potential to be a customized medicine that can "cure" a variety of diseases. Gene therapy generally refers to the transfer of genetic material to treat an illness, or at the very least, to enhance a patient's clinical condition. Using viruses as genetic vectors to deliver the desired gene to the target cells is one method of how gene therapy functions. These vectors are classified as RNA-based or DNA-based viral vectors depending on the type of genome they contain.

The majority of experts concur that gene therapy has the potential to be the most intriguing use of DNA research to date. A simple intravenous injection of a gene transfer agent may one day be used to administer genes as medicine, seeking out target cells for stable, site-specific chromosomal integration and subsequent gene expression. It is predicted that there would be a need for gene therapy using revolutionary techniques that are being tested by researchers around the world and incorporated into conventional treatment is expected to act as driver for the growth of North America gene therapy market

• Increasing prevalance of genetic disorders

A sizable share of prenatal and neonatal mortality in several nations in the Region is caused by genetic and congenital diseases. Many multifactorial ailments are often caused by genetic factors as well. Gene alterations that are essentially present in every cell in the body cause many hereditary diseases. These illnesses thus frequently impact many bodily systems, and the majority cannot be treated.

For instance,

• The Department of Health indicated that roughly six out of ten people will be impacted by an ailment that has some genetic ties, according to the Government of Western Australia. Genetic disorders can range from minor to very severe. Between 3 and 5% of newborns born in Western Australia have genetic disorders or birth abnormalities

Mutations, exposure to chemicals and radiation, among other things, can all result in genetic disorders. Although some ailments have been treated with gene therapy, the majority of treatment plans for genetic disorders do not change the underlying genetic abnormality. For this, the prevalence of genetic abnormalities is significantly rising across all age groups and practically all geographic areas are expected to act as a driver for the growth of North America gene therapy market.

Restraint

• High cost of gene therapy

A new line of medical treatments called gene therapy involves replacing, deleting, or introducing genetic information into a patient's genome in order to treat a condition. Even though it is still in its infancy, gene therapy has already shown tremendous promise for the treatment and even cure of once-intractable illnesses. Gene therapy pricing is still highly uncontrolled and determined on a case-by-case basis in many nations, frequently focusing on a single upfront payment.

For instance,

• According to a news article published in Web MD in February 2023, Hemgenix is breaking records but is hardly an anomaly. In September 2022, Skysona, a medication for a rare neurological condition, went on sale for $3 million. Just one month prior, Zynteglo, a gene treatment for a genetic blood condition, made its market debut for $2.8 million. A cure for the genetic condition spinal muscular atrophy, which kills infants and young children, called Zolgensma cost $2.1 million in 2019.

Even if they are not always fully curative, gene therapies can be really transforming. The main barrier to accessing gene therapy is cost. The treatment landscape for many rare genetic illnesses will undergo significant change as additional gene therapy products become available, providing patients with potentially curative alternatives for the first time. The difficulty of making sure that all patients, not just a small group with financial means and privileged access to technology, may benefit from these cutting-edge therapies must be addressed by healthcare systems around the world. However, due to the high cost of the treatments

Opportunity

• Rise in strategic acquisition and partnership among organizations

Recently, different organizations are stepping forward for partnership and collaboration to develop various gene therapy products that are essential for detecting genetic disorders. Not only this, with the help of partnerships and agreements both the companies can develop a new suite of technologies and platforms that will help to detect diseases.

With the help of a long-term agreement, both companies can provide dimensional pricing of gene therapy products in response to consumer demand in the market. Such partnership and mutual agreement not only benefit both the companies but are also creating a lot of opportunities for the market to grow.

For instance,

• In July 2022, Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+

Therefore, a rise in collaboration & partnerships is further expected to create a lot of opportunities for the market to grow

Challenge

• Stringent regulations for gene therapy products

The use of gene therapy across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis and timely treatments. At the same time, the players of the gene therapy in the market have to follow certain regulations to get approval from the upper authorities for the launching of the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various gene therapy products varies from one country to another.

For instance,

• In 2022, according to the information provided by Food and Drug Administration (FDA), the Center for Biologics Evaluation and Research (CBER) regulates cellular therapy products, human gene therapy products, and certain devices related to cell and gene therapy. CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.

Hence, stringent regulations for gene therapy products is different for different countries which is expected to act as a challenge in the market growth.

Recent Developments

• In December 2022 Kite Pharma, Inc., and Daiichi Sankyo Co., Ltd. announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma. Only patients who have not previously had a transfusion of CAR T cells directed against the CD19 antigen should be treated with Yescarta
• In December, Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy, for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. This has helped the company to expand their product portfolio

North America Gene Therapy Market Scope

The North America gene therapy market is segmented into four notable segments based on vector type, method, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY VECTOR TYPE

• Viral Vector
• Non-Viral Vector

On the basis of vector type, the North America gene therapy market is segmented into viral and non-viral vector.

BY METHOD

• Ex-Vivo
• In-Vivo

On the basis of method, the North America gene therapy market is segmented into ex vivo and in vivo.

BY APPLICATION

• Oncological Disorders
• Cardiovascular Diseases
• Infectious Disease
• Rare Diseases
• Neurological Disorders
• Other Diseases

On the basis of application, the North America gene therapy market is segmented into oncological disorders, cardiovascular diseases, infectious diseases, rare diseases, neurological disorders, and other diseases.

BY END USER

• Cancer Institutes
• Hospitals
• Research Institutes
• Others

On the basis of end user, the North America gene therapy market is segmented into cancer institutes, hospitals, research institutes, and others.

North America Gene Therapy Market Regional Analysis/Insights

The North America gene therapy market is segmented into four notable segments based on vector type, method, application, and end user.

The countries covered in this market report are U.S., Canada, and Mexico.

U.S. is expected to grow due to rise in technological advancement in gene therapy products market.

The U.S. dominates North America region due to strong presence of key players Novartis AG, Kite Pharma. Germany dominates Europe region due to the mass production of gene therapy products and increasing demand from emerging markets and expansion. China dominates Asia-Pacific region due to due to increasing customer inclinations towards minimally invasive medical processes.

La section du rapport sur les pays fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché de la thérapie génique en Amérique du Nord

Le paysage concurrentiel du marché de la thérapie génique en Amérique du Nord fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et la portée du produit, la domination des applications, la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché de la thérapie génique en Amérique du Nord.

Certains des principaux acteurs opérant sur le marché nord-américain de la thérapie génique sont : Novartis AG, Kite Pharma (une filiale de Gilead Sciences, Inc.), uniQure NV, Oxford Biomedica, Spark Therapeutics, Inc., SIBONO, bluebird bio, Inc., Shanghai Sunway Biotech Co. Ltd., Biogen, Dendreon Pharmaceuticals LLC., Amgen Inc., AnGes, Inc. et Enzyvant Therapeutics GmbHAudubon Bioscience, entre autres.

SKU-69929